MediciNova, Inc. (MNOV:NASDAQ) closed at $1.45 on November 5, 2026, unchanged on the day. The stock trades 62.8% below its 52-week high of $3.90 and 18.9% above its 52-week low of $1.22. Over the past year, it gained 3.6%. MediciNova, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 5, 2025, MNOV closed higher on 106 days (42%). Its best day was September 17, 2026 (+36.90%) and its worst was September 28, 2026 (-18.60%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 3 times.
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a Ã2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Find more stocks like MNOV with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.